BlackRock Fund Advisors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-2,454,318
| Closed | -$36.8M | – | 4320 |
|
|
2016
Q2 | $36.8M | Buy |
2,454,318
+162,912
| +7% | +$2.09M | 0.01% | 1698 |
|
|
2016
Q1 | $27.9M | Buy |
2,291,406
+19,031
| +0.8% | +$267K | 0.01% | 1794 |
|
|
2015
Q4 | $36.2M | Buy |
2,272,375
+21,348
| +0.9% | +$336K | 0.01% | 1697 |
|
|
2015
Q3 | $34.5M | Buy |
2,251,027
+101,275
| +5% | +$2.19M | 0.01% | 1661 |
|
|
2015
Q2 | $52.3M | Buy |
2,149,752
+69,346
| +3% | +$1.66M | 0.01% | 1494 |
|
|
2015
Q1 | $48.4M | Buy |
2,080,406
+177,137
| +9% | +$4.69M | 0.01% | 1526 |
|
|
2014
Q4 | $47.8M | Buy |
1,903,269
+162,861
| +9% | +$4.78M | 0.01% | 1493 |
|
|
2014
Q3 | $54.1M | Buy |
1,740,408
+264,944
| +18% | +$7.18M | 0.02% | 1317 |
|
|
2014
Q2 | $38.2M | Buy |
1,475,464
+615,755
| +72% | +$13.7M | 0.01% | 1582 |
|
|
2014
Q1 | $20.1M | Buy |
859,709
+31,972
| +4% | +$699K | 0.01% | 1993 |
|
|
2013
Q4 | $21M | Buy |
827,737
+345,054
| +71% | +$7.79M | 0.01% | 1969 |
|
|
2013
Q3 | $9.85M | Buy |
482,683
+104,779
| +28% | +$2.33M | ﹤0.01% | 2372 |
|
|
2013
Q2 | $7.93M | Buy |
+377,904
| New | +$6.75M | ﹤0.01% | 2401 |
|
BlackRock Fund Advisors's SGNT Position: Q3 2016 in Review
BlackRock Fund Advisors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 2,454,318 shares — an estimated $36.8M sold.
BlackRock Fund Advisors first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $54.1M in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- BlackRock Fund Advisors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- BlackRock Fund Advisors sold 2,454,318 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $36.8M.
- BlackRock Fund Advisors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- BlackRock Fund Advisors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $54.1M in Q3 2014.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on BlackRock Fund Advisors's 13F filing for Q3 2016, filed 8 Nov 2016.